Registry for patients with Primary Immune Thrombocytopenia in Spain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to gather comprehensive epidemiological data on Primary Immune Thrombocytopenia (PIT) and other immune-related thrombocytopenias in Spain. It will include patients of all ages who have been diagnosed with PIT or similar conditions, focusing on their clinical characteristics and treatment histories. The study seeks to enhance understanding of the disease's prevalence and incidence, which is currently lacking in the region. By collecting data from various hospitals, the registry will help characterize the patient population and improve future management strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children as young as 2 months of age and adults in follow-up since 2015 (irrespective of date of diagnosis) with the diagnostic presumption of PIT or other thrombocytopenia of probable immune origin defined as a platelet count \< 100 x 109/L.
* Patients who have given written informed consent. In the case of deceased patients, the data will be included in the registry and the investigator will record the impossibility of collecting patient's informed consent form due to death. Only patients deceased after December 31 2015, will be included

Exclusion Criteria:

* Patients who, at the investigator's discretion, do not meet the conditions for inclusion in the study

Where it's running

• Complexo Hospitalario Universitario A Coruña
  A Coruña, A Coruña, Spain Recruiting
• Hospital Universitario Son Espases
  Palma, Balearic Islands, Spain Recruiting
• Hospital Del Mar
  Barcelona, Barcelona, Spain Recruiting
• Hospital de Basurto
  Bilbao, Biskaia, Spain Recruiting
• Hospital de La Plana
  Castellon, Castellón, Spain Recruiting
• Hospital Universitario Punta de Europa
  Algeciras, Cádiz, Spain Recruiting

Study contacts

• Study coordinator: Cristina Pascual Izquierdo, MD
• Email: sehh@sehh.es
• Phone: 91 586 8445

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multi-target drugs sequentially combine therapy in adults with newly diagnosed immune thrombocytopenia

  This study tests whether starting with standard steroids plus a TPO-RA, then adding a second targeted therapy if needed, can improve platelet counts in adults with newly diagnosed ITP.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07788456

• High-dose dexamethasone plus orelabrutinib versus placebo for newly diagnosed adult ITP

  This trial tests whether adding orelabrutinib to high-dose dexamethasone helps adults newly diagnosed with primary ITP raise and maintain their platelet counts compared with placebo.

  Recruiting Phase 3 Shandong University · Jinan, Shandong · NCT07559331

• CTX112 (zugo-cel) for relapsed/refractory ITP and wAIHA in adults

  This trial tests CTX112, an off-the-shelf CD19 CAR-T therapy, to see if it can help adults with relapsed or refractory ITP or wAIHA.

  Recruiting at 12 sites Phase 1/2 CRISPR Therapeutics · Boston, Massachusetts and 11 other locations · NCT07549698

• Ianalumab plus a thrombopoietin receptor agonist for adults with ITP or Evans syndrome

  This study will test whether adding ianalumab to a doctor's chosen TPO-RA is tolerable for adults with immune thrombocytopenia (and an exploratory group with Evans syndrome) who have had prior treatments and are on a stable TPO-RA dose.

  Recruiting at 23 sites Phase 2 Novartis · Chandler, Arizona and 22 other locations · NCT07421167

• Intravenous immunoglobulin (5%) treatment for primary immune thrombocytopenia

  This study tests whether 5% intravenous immunoglobulin given daily for five days safely raises platelet counts in adults (18–65) with chronic primary ITP and platelet counts below 30 × 10^9/L.

  Recruiting at 9 sites Phase 3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. · Ankara, Altındağ and 8 other locations · NCT07233213

• Efgartigimod IV for adolescents (12–17) with chronic immune thrombocytopenia

  This trial will try intravenous efgartigimod to see if it safely raises platelet counts in people aged 12 to 17 with chronic ITP.

  Recruiting at 26 sites Phase 2/3 argenx · Bordeaux and 25 other locations · NCT07194850

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.